Review



mapk inhibitors 175  (MedChemExpress)


Bioz Verified Symbol MedChemExpress is a verified supplier
Bioz Manufacturer Symbol MedChemExpress manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 95
      Buy from Supplier

    Structured Review

    MedChemExpress mapk inhibitors 175
    Mapk Inhibitors 175, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 155 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitors 175/product/MedChemExpress
    Average 95 stars, based on 155 article reviews
    mapk inhibitors 175 - by Bioz Stars, 2026-02
    95/100 stars

    Images



    Similar Products

    mapk inhibitors 175  (MedChemExpress)
    95
    MedChemExpress mapk inhibitors 175
    Mapk Inhibitors 175, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitors 175/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    mapk inhibitors 175 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    mapk inhibitor u0126  (MedChemExpress)
    95
    MedChemExpress mapk inhibitor u0126
    Mapk Inhibitor U0126, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitor u0126/product/MedChemExpress
    Average 95 stars, based on 1 article reviews
    mapk inhibitor u0126 - by Bioz Stars, 2026-02
    95/100 stars
    		  Buy from Supplier
    mitogen activated protein kinase mapk inhibitors  (MedChemExpress)
    97
    MedChemExpress mitogen activated protein kinase mapk inhibitors
    Effects of hellebrigenin on apoptosis in NPC cells and in an NPC xenograft model. (A, B) <t>MAPK</t> protein expression was assessed using a Western blot assay following hellebrigenin treatment (0, 5, 10 and 20 nM). β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. (C, D) Cells were treated with 10 nM hellebrigenin with or without the ERK inhibitor <t>U0126.</t> β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (E, F) Cells were treated with 10 nM of hellebrigenin with or without the JNK inhibitor JNK‐in‐8. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (G) Tumour volumes of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The seventh day following tumour injection was identified as Day 0. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (H) Body weights of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (I) Immunohistochemical analysis of Ki67 and CHCHD2 expression in the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. Scale bar = 50 μm.
    Mitogen Activated Protein Kinase Mapk Inhibitors, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mitogen activated protein kinase mapk inhibitors/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    mitogen activated protein kinase mapk inhibitors - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    mapk inhibitor u0126  (Millipore)
    90
    Millipore mapk inhibitor u0126
    Effects of hellebrigenin on apoptosis in NPC cells and in an NPC xenograft model. (A, B) <t>MAPK</t> protein expression was assessed using a Western blot assay following hellebrigenin treatment (0, 5, 10 and 20 nM). β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. (C, D) Cells were treated with 10 nM hellebrigenin with or without the ERK inhibitor <t>U0126.</t> β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (E, F) Cells were treated with 10 nM of hellebrigenin with or without the JNK inhibitor JNK‐in‐8. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (G) Tumour volumes of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The seventh day following tumour injection was identified as Day 0. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (H) Body weights of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (I) Immunohistochemical analysis of Ki67 and CHCHD2 expression in the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. Scale bar = 50 μm.
    Mapk Inhibitor U0126, supplied by Millipore, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitor u0126/product/Millipore
    Average 90 stars, based on 1 article reviews
    mapk inhibitor u0126 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    mapk inhibitor  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc mapk inhibitor
    Effects of hellebrigenin on apoptosis in NPC cells and in an NPC xenograft model. (A, B) <t>MAPK</t> protein expression was assessed using a Western blot assay following hellebrigenin treatment (0, 5, 10 and 20 nM). β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. (C, D) Cells were treated with 10 nM hellebrigenin with or without the ERK inhibitor <t>U0126.</t> β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (E, F) Cells were treated with 10 nM of hellebrigenin with or without the JNK inhibitor JNK‐in‐8. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (G) Tumour volumes of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The seventh day following tumour injection was identified as Day 0. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (H) Body weights of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (I) Immunohistochemical analysis of Ki67 and CHCHD2 expression in the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. Scale bar = 50 μm.
    Mapk Inhibitor, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitor/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    mapk inhibitor - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    mapk inhibitors u0126  (Cell Signaling Technology Inc)
    97
    Cell Signaling Technology Inc mapk inhibitors u0126
    Effects of hellebrigenin on apoptosis in NPC cells and in an NPC xenograft model. (A, B) <t>MAPK</t> protein expression was assessed using a Western blot assay following hellebrigenin treatment (0, 5, 10 and 20 nM). β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. (C, D) Cells were treated with 10 nM hellebrigenin with or without the ERK inhibitor <t>U0126.</t> β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (E, F) Cells were treated with 10 nM of hellebrigenin with or without the JNK inhibitor JNK‐in‐8. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (G) Tumour volumes of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The seventh day following tumour injection was identified as Day 0. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (H) Body weights of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (I) Immunohistochemical analysis of Ki67 and CHCHD2 expression in the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. Scale bar = 50 μm.
    Mapk Inhibitors U0126, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitors u0126/product/Cell Signaling Technology Inc
    Average 97 stars, based on 1 article reviews
    mapk inhibitors u0126 - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier
    mapk inhibitor  (TargetMol)
    94
    TargetMol mapk inhibitor
    Effects of hellebrigenin on apoptosis in NPC cells and in an NPC xenograft model. (A, B) <t>MAPK</t> protein expression was assessed using a Western blot assay following hellebrigenin treatment (0, 5, 10 and 20 nM). β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. (C, D) Cells were treated with 10 nM hellebrigenin with or without the ERK inhibitor <t>U0126.</t> β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (E, F) Cells were treated with 10 nM of hellebrigenin with or without the JNK inhibitor JNK‐in‐8. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (G) Tumour volumes of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The seventh day following tumour injection was identified as Day 0. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (H) Body weights of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (I) Immunohistochemical analysis of Ki67 and CHCHD2 expression in the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. Scale bar = 50 μm.
    Mapk Inhibitor, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/mapk inhibitor/product/TargetMol
    Average 94 stars, based on 1 article reviews
    mapk inhibitor - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    erk1 2 mapk inhibitor u0126  (MedChemExpress)
    97
    MedChemExpress erk1 2 mapk inhibitor u0126
    Effects of hellebrigenin on apoptosis in NPC cells and in an NPC xenograft model. (A, B) <t>MAPK</t> protein expression was assessed using a Western blot assay following hellebrigenin treatment (0, 5, 10 and 20 nM). β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. (C, D) Cells were treated with 10 nM hellebrigenin with or without the ERK inhibitor <t>U0126.</t> β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (E, F) Cells were treated with 10 nM of hellebrigenin with or without the JNK inhibitor JNK‐in‐8. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (G) Tumour volumes of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The seventh day following tumour injection was identified as Day 0. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (H) Body weights of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (I) Immunohistochemical analysis of Ki67 and CHCHD2 expression in the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. Scale bar = 50 μm.
    Erk1 2 Mapk Inhibitor U0126, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 97/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/erk1 2 mapk inhibitor u0126/product/MedChemExpress
    Average 97 stars, based on 1 article reviews
    erk1 2 mapk inhibitor u0126 - by Bioz Stars, 2026-02
    97/100 stars
    		  Buy from Supplier

    Image Search Results


    Effects of hellebrigenin on apoptosis in NPC cells and in an NPC xenograft model. (A, B) MAPK protein expression was assessed using a Western blot assay following hellebrigenin treatment (0, 5, 10 and 20 nM). β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. (C, D) Cells were treated with 10 nM hellebrigenin with or without the ERK inhibitor U0126. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (E, F) Cells were treated with 10 nM of hellebrigenin with or without the JNK inhibitor JNK‐in‐8. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (G) Tumour volumes of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The seventh day following tumour injection was identified as Day 0. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (H) Body weights of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (I) Immunohistochemical analysis of Ki67 and CHCHD2 expression in the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. Scale bar = 50 μm.

    Journal: Journal of Cellular and Molecular Medicine

    Article Title: The Efficacy of Hellebrigenin Against Nasopharyngeal Carcinoma Cells: The Molecular and Bioinformatic Analysis

    doi: 10.1111/jcmm.70624

    Figure Lengend Snippet: Effects of hellebrigenin on apoptosis in NPC cells and in an NPC xenograft model. (A, B) MAPK protein expression was assessed using a Western blot assay following hellebrigenin treatment (0, 5, 10 and 20 nM). β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. (C, D) Cells were treated with 10 nM hellebrigenin with or without the ERK inhibitor U0126. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (E, F) Cells were treated with 10 nM of hellebrigenin with or without the JNK inhibitor JNK‐in‐8. β‐Actin was identified as the internal control. The results are presented as mean ± SD, n = 3. * p < 0.05 compared with 0 nM. # p < 0.05 compared with hellebrigenin 10 nM. (G) Tumour volumes of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The seventh day following tumour injection was identified as Day 0. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (H) Body weights of the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. The results are presented as mean ± SE, n = 3. * p < 0.05 compared with vehicle. (I) Immunohistochemical analysis of Ki67 and CHCHD2 expression in the vehicle group and NPC xenograft mice treated with 4 mg/kg of hellebrigenin. Scale bar = 50 μm.

    Article Snippet: Hellebrigenin (purity ≥ 99%, Figure ) and mitogen‐activated protein kinase (MAPK) inhibitors (U0126 and JNK‐in‐8) were purchased from MedChemExpress (Monmouth Junction, NJ, USA).

    Techniques: Expressing, Western Blot, Control, Injection, Immunohistochemical staining